A
Alina S. Gerrie
Researcher at University of British Columbia
Publications - 114
Citations - 1375
Alina S. Gerrie is an academic researcher from University of British Columbia. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 19, co-authored 87 publications receiving 961 citations. Previous affiliations of Alina S. Gerrie include The New School & Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era
Robert Kridel,David Telio,David Telio,Diego Villa,Diego Villa,Laurie H. Sehn,Laurie H. Sehn,Alina S. Gerrie,Alina S. Gerrie,Tamara Shenkier,Richard Klasa,Richard Klasa,Graham W. Slack,King Tan,Randy D. Gascoyne,Joseph M. Connors,Joseph M. Connors,Kerry J. Savage,Kerry J. Savage +18 more
TL;DR: The addition of rituximab has reduced the risk of lymphoma recurrence in testicular DLBCL, presumably through improved eradication of systemic disease, but central nervous system relapse risk remains high and further studies evaluating effective prophylactic strategies are needed.
Journal ArticleDOI
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Ciara L. Freeman,Robert Kridel,Alden A. Moccia,Kerry J. Savage,Diego Villa,David W. Scott,Alina S. Gerrie,David J. P. Ferguson,Fergus Cafferty,Graham W. Slack,Pedro Farinha,Brian Skinnider,Joseph M. Connors,Laurie H. Sehn +13 more
TL;DR: Compared to a historical cohort treated with RCVP, EFS has improved and the risk of POD24 has decreased, but a higher proportion of patients with POD 24 harbor transformation, and the overall incidence of transformation appears unchanged.
Journal ArticleDOI
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
James N. Gerson,Elizabeth Handorf,Diego Villa,Alina S. Gerrie,Parv Chapani,Shaoying Li,L. Jeffrey Medeiros,Michael I. Wang,Jonathon B. Cohen,Oscar Calzada,Michael C. Churnetski,Brian T. Hill,Yazeed Sawalha,Francisco J. Hernandez-Ilizaliturri,Shalin Kothari,Julie M. Vose,Martin Bast,Timothy S. Fenske,Swapna Narayana Rao Gari,Kami J. Maddocks,David A. Bond,Veronika Bachanova,Bhaskar Kolla,Julio C. Chavez,Bijal D. Shah,Frederick Lansigan,Timothy F. Burns,Alexandra M. Donovan,Nina D. Wagner-Johnston,Marcus Messmer,Amitkumar Mehta,Jennifer Kelly Anderson,Nishitha Reddy,Alexandra E. Kovach,Daniel J. Landsburg,Martha Glenn,David J. Inwards,Reem Karmali,Jason B. Kaplan,Paolo Caimi,Saurabh Rajguru,Andrew M. Evens,Andreas K. Klein,Elvira Umyarova,Bhargavi Pulluri,Jennifer E Amengual,Jennifer K. Lue,Catherine Diefenbach,Richard I. Fisher,Stefan K. Barta +49 more
TL;DR: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis, and it is suggested that in younger, fit patients,AHCT consolidation may improve PFS.
Journal ArticleDOI
Observation as the initial management strategy in patients with mantle cell lymphoma
Pau Abrisqueta,Pau Abrisqueta,David W. Scott,Graham W. Slack,Christian Steidl,Anja Mottok,Randy D. Gascoyne,Jean M. Connors,Laurie H. Sehn,Kerry J. Savage,Alina S. Gerrie,Diego Villa +11 more
TL;DR: A subgroup of patients with MCL may be safely observed from diagnosis without negatively impacting their outcomes, including patients with non-nodal presentation as well as asymptomatic patients with low burden nodal presentation and a low proliferative rate.
Journal ArticleDOI
High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.
Lauren C. Chong,Susana Ben-Neriah,Graham W. Slack,Ciara L. Freeman,Daisuke Ennishi,Anja Mottok,Brett Collinge,Pau Abrisqueta,Pedro Farinha,Merrill Boyle,Barbara Meissner,Robert Kridel,Alina S. Gerrie,Diego Villa,Kerry J. Savage,Laurie H. Sehn,Reiner Siebert,Ryan D. Morin,Randy D. Gascoyne,Marco A. Marra,Joseph M. Connors,Andrew J. Mungall,Christian Steidl,David W. Scott +23 more
TL;DR: The data reveal clinically relevant architecture of MYC rearrangements in lymphomas with DLBCL morphology and shows a trend toward inferior time to progression and overall survival compared with MYC-non-IG rearrangement.